Clinical trials: Normal Responders
Rheumatoid Arthritis
Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching…
- Trial name
- NCT01668641
- Testing
- GLPG0634
- Where
- 19 sites in Hungary, Moldova and 2 more
- Volunteers
- 91 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia
Purpose of the study is to determine if Cimzia is safe and effective in subjects who have received previous treatment with a TNF-alpha inhibitor other than Cimzia.
- Trial name
- NCT01147341
- Testing
- Cimzia
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- Michael Schiff, MD
Fertility Disorders
Prospective Randomized Trial Comparing Corifollitropin-alfa Late Start vs. Corifollitropin-alfa Standard Start in Expected Poor, Normal and High-responders Undergoing IVF
To compare the number of retrieved oocytes in the late start CF-alfa (day 4) versus standard CF-alfa protocols (day 2) in patients undergoing IVF.
- Trial name
- NCT03816670
- Testing
- Corifollitropin Alfa
- Where
- Italy
- Volunteers
- 113 people
- Sponsor
- University of Turin, Italy
Inflammation, Rheumatoid Arthritis
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly…
- Trial name
- NCT01636843
- Testing
- NNC0109-0012
- Where
- 139 sites in United States, Argentina and 12 more
- Volunteers
- 298 people
- Sponsor
- Novo Nordisk A/S
Atopic Dermatitis
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18…
- Trial name
- NCT05018806
- Testing
- Rilzabrutinib
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Inflammation, Rheumatoid Arthritis
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly s.c.
- Trial name
- NCT01636817
- Testing
- NNC0109-0012
- Where
- 164 sites in United States, Argentina and 11 more
- Volunteers
- 239 people
- Sponsor
- Novo Nordisk A/S
Rheumatoid Arthritis
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Primary Objective: To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for: reduction of signs and symptoms at Week 24 and improvement of physical function at Week 12 in…
- Trial name
- NCT01709578
- Testing
- Sarilumab, hydroxychloroquine, methotrexate
- Where
- 196 sites in United States, Argentina and 28 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
Lung Disease, Interstitial
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases
The purpose of the study is to evaluate the efficacy on lung function 6 months after one course of rituximab (2 infusions) and mycophénolate mofétil (MMF) treatment compared to one course of placebo and 6 months of MMF treatment…
- Trial name
- EvER-ILD (NCT02990286)
- Testing
- Rituximab, Mycophenolate Mofetil
- Where
- 5 sites in France
- Volunteers
- 122 people
- Sponsor
- University Hospital, Tours
Ovarian Stimulation
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle…
- Trial name
- FSH (NCT06572930)
- Testing
- Gonal-f (gonadotropin)
- Where
- United Arab Emirates
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- ART Fertility Clinics LLC
Infertility
Follicular Activation in Poor Responders
This study aims to assess whether activation of primordial follicles through ovarian cortex fragmentation may increase the number of antral follicles present in the ovary of patients with diminished ovarian reserve.
- Trial name
- FAPPOR (NCT02354963)
- Testing
- In vitro fragmentation of the ovarian tissue
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- César Díaz García
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Arthritis, Rheumatoid
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT05198310
- Testing
- KPL-404
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 145 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Infertility, Female
150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial
This is a single-center, randomized, open-label, non-inferiority trial comparing two fixed daily doses of follicle-stimulating hormone (FSH): 150 IU versus 225 IU in women with predicted normal ovarian response undergoing in…
- Trial name
- OPTIMAL-DOSE (NCT07346235)
- Testing
- Follicle-stimulating hormone (FSH)
- Where
- Kosovo
- Volunteers
- 440 people
- Sponsor
- American Hospital 2 Kosovo
Rheumatoid Arthritis
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)
Participants suffering from active rheumatoid arthritis despite continued treatment with methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50 milligram [mg], 100…
- Trial name
- DARWIN1 (NCT01888874)
- Testing
- GLPG0634
- Where
- 142 sites in United States, Argentina and 20 more
- Volunteers
- 599 people
- Sponsor
- Lakefront Biotherapeutics NV
Ivf
Opt-IVF for Personalized Medicine for Normal Responders
A clinical trial will determine the effectiveness of the Opt-IVF decision-support tool in generating personalized, optimal drug-dosage profiles for each patient in the United States.
- Trial name
- NCT07856082
- Testing
- Opt-IVF, control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Urmila DIwekar
Female Pattern Hair Loss, Androgenetic Alopecia
Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil
5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female pattern hair loss. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low…
- Trial name
- NCT02486848
- Testing
- 5% Topical Minoxidil Solution, 15% Topical Minoxidil Solution
- Where
- Italy
- Sponsor
- Maja Kovacevic, MD
Androgen Receptor Gene Overexpression, Normal Responders
Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response
AR is a steroid hormone receptor that regulates various genes' expression and affects cellular proliferation and differentiation.
- Conditions
- Androgen Receptor Gene Overexpression, Normal Responders, Poor Ovarian Response, Bologna Criteria
- Trial name
- NCT03433768
- Testing
- Real time PCR
- Volunteers
- 67 people
- Sponsor
- Aristotle University Of Thessaloniki
Infertility
Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
The purpose of this study is to compare the efficacy of two controlled ovarian stimulation protocols, the GnRH agonist protocol, widely known as the "long" protocol, and the flexible GnRH antagonist protocol, in terms of…
- Trial name
- NCT00417183
- Testing
- Arvekap 0.1 mg (Triptorelin, Ipsen, France), Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)
- Where
- Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Eugonia
Cutaneous Melanoma, Mucosal Melanoma
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits.
- Trial name
- Neo IRENIE (NCT06999980)
- Testing
- Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg
- Where
- Australia
- Volunteers
- 494 people
- Sponsor
- Melanoma Institute Australia
Osteosarcoma, Ewing Sarcoma
Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
Primitive bone sarcoma are rare tumors with low options of therapy for patient treatment. 1. OSTEOSARCOMA VERY POOR RESPONDER COHORT.
- Trial name
- Metform-Bone (NCT04758000)
- Testing
- Metformin Hydrochloride
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Istituto Ortopedico Rizzoli